PET tracer starts phase I trial:
This article was originally published in Clinica
FluoroPharma is to begin phase I clinical trials of its imaging agent BFPET, following US institutional review board approval of the proposed studies. The planned trial will evaluate safety, distribution, and dosimetry of BFPET as a positron emission tomography (PET) blood flow tracer for myocardial perfusion imaging in healthy subjects. More than nine million patients undergo myocardial perfusion imaging - the standard test to assess coronary artery disease - annually in the US. Boston, Massachusetts-based FluoroPharma is a subsidiary of QuantRx.